Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Escalation Arm News

Escalation Arm News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Escalation Arm. Real-time updates on events, politics, business and more.

Celcuity Inc.: Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

May 12, 2023
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian
San Antonio United States Vicky Hahne Robert Uhl Brian Sullivan Igor Gorbatchevsky
Source: finanznachrichten.de

Celcuity Inc.: Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

December 9, 2022
High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported
Vicky Hahne Kostenloser Wertpapierhandel Robert Uhl Brian Sullivan Exchange Commission On Celcuity Inc
Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science